Capsules: acute diarrhea of infectious origin in children and adults; chronic colitis, enterocolitis of infectious origin; in the complex treatment of intestinal dysbacteriosis, for the prevention of infectious complications from the gastrointestinal tract during surgical interventions.

Hypersensitivity to nifuroxazid, other components of the preparation, as well as to other derivatives of 5-nitrofuran. for the preparation in the form of capsules: age up to 7 years (children up to 7 years old use nifuroxazid-Sperco in the form of a suspension).

Capsules: adults and children older than 7 years are prescribed 1 capsule 4 times a day, regardless of meals.

The maximum daily dose of nifuroxazid is 800 mg. The duration of treatment should not exceed 7 days.

During treatment, it is forbidden to drink alcohol due to the risk of developing a disulfiram-like reaction, which is manifested by exacerbation of diarrhea, vomiting, abdominal pain, a feeling of heat in the face and upper half of the body, hyperemia, tinnitus, difficulty breathing, tachycardia.

There are no sufficient data on possible teratogenic and fetotoxic effects when using nifuroxazide during pregnancy. Therefore, as a precautionary measure, the use of nifuroxazide during pregnancy is not recommended.

The preparation can be used by women during breastfeeding during short-term treatment with Nifuroxazid.

Children

Nifuroxazid-Sperco in the form of capsules is prescribed to children aged 7 years and older. For the treatment of children under the age of 7, Nifuroxazid-Sperco is prescribed in the form of a suspension.

To the drivers

Does not affect.

Capsules, suspension. cases of overdose have not been described. in case of overdose, gastric lavage and symptomatic treatment are recommended.

Capsules. the preparation is well tolerated, occasionally temporary abdominal pain, nausea, vomiting, and increased diarrhea may occur. in the event of the appearance of symptoms from the gastrointestinal tract of minor intensity, there is no need to use special therapy or stop using nifuroxazide, since these symptoms disappear on their own.

Patients with hypersensitivity to nitrofuran derivatives may experience granulocytopenia; allergic reactions, as a rule, of the skin type (skin rash, itching, urticaria, pustulosis). In rare cases, as with the use of other nitrofuran derivatives, shortness of breath, severe hypersensitivity reactions, including angioedema and anaphylactic shock, may occur.

In case of severe adverse reactions, the preparation should be discontinued and symptomatic therapy should be carried out. In the future, the patient should avoid taking nifuroxazide and other nitrofuran derivatives.

Nifuroxazid is not recommended to be used simultaneously with sorbents, preparations that include alcohol, preparation that can cause antabuse reactions, and preparatios that depress the central nervous system.